A transcriptomics-guided drug target discovery strategy identifies receptor ligands for lung regeneration

Xinhui Wu 1,2, I. Sophie T. Bos 1,2, Thomas M. Conlon 3, Meshal Ansari 3, Vicky Verschut 1,4, Luke van der Koog 1,2, Lars A. Verkleij 1,2, Angela D’Ambrosi 1,2, Aleksey Matveenko 5, Herbert B. Schiller 3, Melanie Königshoff 6, Martina Schmidt 1,2, Loes E. M. Kistemaker 1,2,4, Ali Önder Yildirim 3, Reinoud Gosens 1,2,*

Currently, there is no pharmacological treatment targeting defective tissue repair in chronic disease. Here, we used a transcriptomics-guided drug target discovery strategy using gene signatures of smoking-associated chronic obstructive pulmonary disease (COPD) and from mice chronically exposed to cigarette smoke, identifying druggable targets expressed in alveolar epithelial progenitors, of which we screened the function in lung organoids. We found several drug targets with regenerative potential, of which EP and IP prostanoid receptor ligands had the most profound therapeutic potential in restoring cigarette smoke–induced defects in alveolar epithelial progenitors in vitro and in vivo. Mechanistically, we found, using single-cell RNA sequencing analysis, that circadian clock and cell cycle/apoptosis signaling pathways were differentially expressed in alveolar epithelial progenitor cells in patients with COPD and in a relevant model of COPD, which was prevented by prostaglandin E2 or prostacyclin mimetics. We conclude that specific targeting of EP and IP receptors offers therapeutic potential for injury to repair in COPD.

INTRODUCTION

One of the main challenges in pharmacology today is the generation of drugs with regenerative potential, with the ability to restore tissue repair in chronic disease. Regenerative medicine has thus far mainly focused on transplantation, tissue engineering approaches, stem or progenitor cell therapy, or a combination of these (1). A regenerative pharmacological approach will have considerable additional potential because it can be applied on a relatively large scale. Furthermore, it can be used to halt the disease process in an early stage, resulting in real disease-modifying treatment. In addition, pharmaceutical targeting may aid or support other regenerative strategies.

There is a need for regenerative pharmacology in respiratory, cardiovascular, and neurological diseases as well as many other disease areas. In respiratory medicine, chronic obstructive pulmonary disease (COPD) is one of the most common lung diseases with a need for regenerative therapies. The disease is characterized by airflow limitation that is not fully reversible and which deteriorates progressively. The main difficulty underlying COPD pathogenesis is increased tissue destruction in combination with abnormal tissue repair in susceptible individuals. As current therapies do not modify the course of the disease, developing new therapeutic strategies aiming at regeneration of tissue is necessary.

In affected individuals, there is an increase in alveolar air space associated with destruction of alveolar epithelial cells along with reduced capacity of epithelial progenitors to restore this defect. In the distal lung, alveolar type II cells and alveolar epithelial progenitors harbor stem cell capacity and function to maintain alveolar epithelium (2). These cells reside in a local tissue microenvironment called the niche, which is composed of supporting cells such as fibroblasts and alveolar macrophages. The niche controls adequate activation of the progenitor cell (1–3) by means of secreted factors such as Wingless-related integration sites (WNTs), fibroblast growth factors (FGFs), retinoic acid, and many other factors that control stemness, proliferation, and differentiation (3).

As in many chronic diseases associated with aging, this local lung microenvironment is insufficiently supportive for lung repair in COPD (1, 4, 5). For example, studies have indicated that an imbalance of canonical and noncanonical WNT signaling results in impaired alveolar regeneration in COPD (4, 6). Moreover, lymphotixin-β (LTβ), released from CD8+ T cells in COPD, can interfere with Wntβ-catenin signaling, thereby repressing functional Wnt/β-catenin signaling in the lung (5). A recent study showed longitudinal changes in lung tissue gene expression associated with repair to underlying disease progression (7). Accordingly, the challenge of successful regenerative pharmacology in COPD needs to take into consideration the specific hostile microenvironment and the abnormal repair process that stands in the way of adequate regeneration in COPD.

In the present study, we hypothesized that a transcriptomics-guided drug target discovery strategy based on gene signatures differentially expressed in COPD and in response to cigarette smoke (CS) may be used to identify druggable gene targets that are specifically involved in defective lung repair in COPD. Our results demonstrate that such a strategy coupled to functional studies in organoids yields receptor ligands of which EP and IP prostanoid receptors show the most significant potential in counteracting the negative effects of CS on alveolar progenitor cell function.
RESULTS
Transcriptomics-guided screening to identify drug targets
We set out to identify drug targets that may help restore defective lung repair. To achieve this, we used a transcriptomics-guided target discovery strategy (described in Fig. 1A) based on gene signatures of COPD lung tissues (8) and of a model of CS exposure (9) to identify differentially regulated druggable genes. We found reactome pathways related to inflammation such as neutrophil degranulation and innate immune system to be enriched in both datasets (Fig. 1, C and D) and pathways related senescence, apoptosis,
and extracellular matrix regulation to be enriched in COPD, which was also reported in a recent study (7) using longitudinal samples. We identified 38 individual target genes that were concordantly up-regulated and 30 individual target genes concordantly down-regulated. These genes were filtered through the “Drug-gene interaction and potential druggability in the Drug Gene Interaction Database” (www.dgidb.org), which rendered 25 druggable up-regulated genes and 16 druggable down-regulated genes (Fig. 1B). Genes were further filtered for expression in lung epithelial cells or fibroblasts by consulting the human Lung Cell Atlas (https://asthma.cellgeni.sanger.ac.uk/) and LungMAP (https://lungmap.net/), which yielded 15 druggable target genes.

To assess the potential relevance of signaling functionally associated with the 15 genes of interest, we set up an in vitro organoid model to perform specific drug screening tests. An adult lung epithelial organoid model can recapitulate the in vivo functionality and genetic signature of alveolar epithelium and follow the initial progenitor cell division, subsequent growth, and differentiation of adult lung epithelial cells in a single assay (6, 10). Moreover, the organoid assay allows us to model the interactions between CS extract (CSE) exposure and the alveolar progenitor cell in the most direct possible way. The majority (~70%) of organoids express mature alveolar markers such as pro-SPC (surfactant protein C). Approximately 10% express airway markers [acetylated tubulin (ACT)], and ~10% expressed a mixed phenotype (pro-SPC+/ACT−) (10). Fibroblasts do not integrate into the organoids, which consist entirely of epithelial structures. Thus, we cocultured mouse CD31+/CD45+/Epcam+ (epithelial cellular adhesion molecule+) lung epithelial cells with murine CCL-206 lung fibroblasts or human CD31−/CD45−/Epcam+ lung epithelial cells with human MRC5 (Medical Research Council cell strain) 5 lung fibroblasts in organoids in Matrigel and exposed these in vitro to different concentrations of CSE (Fig. 2, A and C). The number and size of organoids established by coculturing human lung tissue–derived CD31+/CD45+/Epcam+ cells and MRC5 fibroblasts were significantly decreased by CSE in a concentration–dependent manner at day 14 (Fig. 2B). The total number of murine organoids quantified at day 14 of treatment with different concentrations of CSE yielded similar results and was decreased in a CSE dose–dependent manner as well (Fig. 2E). To specifically analyze the impact of CSE on organoids derived from alveolar epithelial progenitors, we morphologically subclassified organoids into airway- and alveolar-type (10) organoids (Fig. 2D), which revealed that alveolar organoid numbers were more susceptible to CSE exposure than airway organoids (Fig. 2E). Immunofluorescence studies confirmed that the number of ACT+ (ciliated cell marker, airway-type organoids) and pro-SPC+ (type II cell marker, alveolar–type organoids) organoids was significantly decreased by 5% CSE (Fig. 2F). The size of both organoid types was decreased at day 14 (Fig. 2G).

We next aimed to use this lung organoid model to evaluate the efficacy of ongoing COPD therapeutics. Increasing evidence (11, 12) has linked phosphodiesterase 4 (PDE4) inhibition to the therapeutic management of respiratory diseases, and roflumilast has been used as an oral medication in patients with COPD with a prior history of hospitalization for an acute exacerbation (GOLD 2021). This led us to explore whether the classic PDE4 inhibitor, rolipram, was able to rescue the CSE–induced reduction in organoid formation by alveolar progenitors. Thus, organoids were subjected in vitro to different concentrations (1 and 10 μM) of rolipram in the presence and absence of 5% CSE for up to 14 days (Fig. S1A). Rolipram (10 μM) alone significantly increased the total number of organoids at day 7 and the pro-SPC+ organoids at day 14 (fig. S1, B and C) but had no beneficial effects on organoid numbers when combined with CSE exposures. Treatment with rolipram (1 μM) either alone or in combination with CSE induced significantly increase alveolar organoid size (fig. S1D). The combination of rolipram and olodaterol tended to restore the defective organoid formation under the exposure of 5% CSE (fig. S1, K to M).

Budesonide is an inhaled corticosteroid used in COPD management (13–16). Therefore, we examined its effect also in our in vitro (fig. S1E) and in vivo (fig. S1H) CS/organoid models. Budesonide (1, 10, and 100 nM) in combination with CSE exposure further reduced the number and the size of both airway- and alveolar–type organoids as compared to CSE exposure alone (fig. S1, F and G). In vivo exposure to budesonide together with CS increased the number of airway but not alveolar organoids (fig. S1I), without affecting the organoid size (fig. S1J). Together, these data show that in vitro exposure to CSE functionally represses human alveolar epithelial progenitor organoid formation, resulting in reduced growth and differentiation, which can be mimicked using murine alveolar epithelial progenitors. Validating the limitations of current pharmacology, PDE4 inhibitors and corticosteroids do not prevent or reduce the detrimental effects of CSE on organoid formation.

The assay was used subsequently to screen for the functionality of the targets in restoring organoid growth. Genes down-regulated in response to CS and COPD were targeted with activating ligands or with ligands mimicking an active state of the protein, whereas genes up-regulated in response to CS and COPD were targeted using antagonists, with the exception of ACSS2 and CHRM3 for which we included both an agonist and an antagonist. In addition, we included an agonist of PTGIR because of its previously suggested beneficial effects in COPD (17). The effects of the drugs targeting the 15 selected genes alone (compared to vehicle; Fig. 2H) and in the presence of 5% CSE exposure (Fig. 2I) on the number of organoids were determined. Specific information of all drug effects on organoid number and size are summarized in figs. S2 and S3. The compound activating ACSS2 [acetyl coenzyme A (CoA) synthetase short–chain family member 2] increased the number of airway–type organoids and the size of alveolar organoids in combination with CSE (figs. S2 and S3), whereas the ACSS2 inhibitor had the opposite effects. Atropine [muscarnic M3 receptor (CHRM3) antagonist], IBSP (integrin binding sialoprotein), and LEPR (leptin receptor) tended to increase the number and size of alveolar organoids in response to CSE as well (figs. S2 and S3). However, considering the overall magnitude of alveolar–type organoids, particularly, 16,16-dimethyl prostaglandin E2 (PGE2) (stable analog of PGE2, the enzymatic product of target gene PTGES) and iloprost [prostacyclin (PGI2) analog, ligand for target gene PTGIR] were identified as the by far most promising targets with regards to their capacity in restoring the CSE–induced repression of organoid formation (Fig. 2, H and I, and fig. S5).

**PGE2 and PGI2 significantly prevent alveolar epithelial dysfunction**

The PTGES2 and PTGIR genes encode membrane–associated PGE synthase and the PGI2 receptor, respectively. PGE2 acts on four receptor subtypes, being PTGER1 to PTGER4, whereas PGI2 acts primarily on PTGIR. We assessed their expression in human lung tissue of healthy smokers and patients with COPD (GSE76925) and
Fig. 2. CS exposure represses adult epithelial lung organoid formation. (A) Schematic of in vitro human experimental design. (B) Quantification of total amount of human organoids and the quantification of average human organoid diameters after treatment with CSE (0, 1, 2.5, and 5%), N = 7 experiments (two healthy and five COPD donors), n > 150 organoids per group. (C) Schematic of in vitro murine experimental design. (D) Representative images of murine lung organoids. Left: Light microscopy. Right: Immunofluorescence (IF) of organoids. Green, pro-SPC (SPC); red, ACT; blue, 4′,6-diamidino-2-phenylindole (DAPI). White arrowheads, airway-type organoid; yellow arrowheads, alveolar-type organoid. Scale bars, 100 μm. (E) Quantification of the normalized number of total organoids, airway, and alveolar-type organoids on day 14 obtained after treatment with different concentrations of CSE (0, 1.25, 2.5, and 5%). (F) Quantification of normalized ACT* and pro-SPC* organoids obtained after treatment with 0, 1.25, 2.5, and 5% CSE. (G) Quantification of average organoid diameter after treatment with 0, 1.25, 2.5, and 5% CSE measured on day 14. N = 5 experiments, n > 380 organoids per group. (H and I) Overview of drug screening using the in vitro murine lung organoid model. Comparison of the normalized number of airway and alveolar-type organoids treated with the different drugs of interest in the absence (H) or presence (I) of 5% CSE. Red bars, PTGIR; yellow bars, PTGES2; blue bars, antagonists. Data are presented as means ± SEM in number quantification. Data are presented as scatter plots with medians in size quantification. VEH, vehicle; ACSS2, acetate-dependent acetyl CoA synthetase 2; CHRM3, muscarinic M3 receptor; CPS1, carbamoyl phosphate synthetase 1; CTSC, cathepsin C; CXCL1, C-X-C motif chemokine ligand 1; DMKN, dermokine; FGF17, fibroblast growth factor 17; IBSP, integrin binding sialoprotein; LEPR, leptin receptor; PTGIR, prostaglandin I receptor; PTGES2, prostaglandin E synthase 2; RAB8B, Ras-related protein Rab-8B; SLC1A4, solute carrier family 1 member 4; SLC16A3, solute carrier family 16 member 3; TNNIK3, TNNI3 interacting kinase. For all panels, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
found maintained expression of all receptors in disease with some small differences in expression, most notably a reduced expression of PTGER2 and increased expression of PTGIR (Fig. 3A). Single-cell RNA sequencing (scRNA-seq) data from human lung tissue shows similar expression of all five receptors in alveolar epithelial cells and in fibroblasts (www.copdcellatlas.com) (18). scRNA-seq of mouse lung tissue shows that expression of Ptger2 and Ptger4 were the highest compared to that of Ptger1 and Ptger3 in mesenchymal cells (Fig. 3, B and C). The expression of PTGES and PTGES2, the enzymes responsible for PGE2 synthesis, was relatively ubiquitous in human and mouse lung tissue, whereas PTGIS, the enzyme responsible for PGI2 synthesis, was the highest in mesenchymal cell types including fibroblasts.

To further characterize the effects of PGE2 and PGI2 on defective alveolar epithelial progenitors, we examined them in vitro (Fig. 3, D to F) and in vivo (Fig. 4) CS(E). The PGE2 analog 16,16-dimethyl PGE2 and the PGI2 analog iloprost both increased the number of alveolar-type organoids even in the presence of 5% CSE (Fig. 3D) and significantly increased the number of SPC+ organoids under conditions of CSE exposure (Fig. 3E). To address the relative roles of the two Gs-coupled PGE2 receptors, EP2 and EP4, we evaluated the selective agonists [(R)-butaprost and 5-[(3S)-3-hydroxy-4-phenyl-1-buten-1-yl][1-6-(2H-tetrazol-5R-yl)hexyl]-2-pyrrolidinone; CAY10598] of these receptors. Focus was on these Gs-coupled receptors, as we found that cholera toxin, a well-known inducer of constitutive adenylyl cyclase activity and adenosine 3′,5′-monophosphate (cAMP) signaling, increased organoid formation both with and without the exposure to CSE (fig. S4A). The EP2-selective butaprost had no effect on organoid number (Fig. 3F) but increased the alveolar size in the absence and presence of 5% CSE.
Fig. 4. Administration (in vivo and in vitro) of misoprostol and iloprost to CS-exposed mice restored lung organoid formation. (A) Schematic of in vivo CS exposure experimental setup. (B and C) Number of airway- and alveolar-type organoids quantified on day 14 of coculturing CCL-206 fibroblasts and Epcam+ cells (isolated from air-exposed/CS-exposed mice). N = 11 experiments. (D) Schematic of experimental design. Organoids were generated from air- or CS-exposed mice treated in vivo with misoprostol [intraperitoneal (i.p.)] or iloprost (intraperitoneal); all organoids were treated with normal organoid medium. (E and F) Number of alveolar-type and pro-SPC+ organoids quantified on day 14 from coculture of CCL-206 fibroblasts and Epcam+ cells [isolated from air-exposed (control) and CS-exposed mice treated intraperitoneally with misoprostol or iloprost]. (G) Schematic of experimental design. Organoids were generated from mice exposed to air or CS. Misoprostol and iloprost were added in vitro to the organoid medium for treatment. (H and I) Number of alveolar-type and SPC+ organoids quantified on day 14 from coculture of CCL-206 fibroblasts and Epcam+ cells [isolated from air- and CS-exposed mice for 4 months] treated with misoprostol/iloprost in vitro. Data are presented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
The EP4-selective agonist increased the number of alveolar-type organoids significantly and prevented the number reduction resulting from 5% CSE exposure (Fig. 3F). The EP4 agonist also increased the size of both types of organoids in the absence and presence of 5% CSE (Fig. S5). To explore whether the duration of drug exposure affected organoid formation, we treated the organoids in vitro with PGE2 or PG12 analog for three different time windows during organoid development as illustrated in fig. S5 (D to G). These time windows were identified previously (10) and mark the initial division phase (days 0 to 2), proliferation (days 2 to 7), and differentiation phase (days 7 to 14). We observed no effect on the number of organoids for any of the short-term drug treatments, suggesting that continuous treatment with or iloprost during all phases of organoid formation is required.

To examine the effects of PGE2 and PG12 in vivo, we exposed mice to air (vehicle control), CS, CS + misoprostol (PGE2 analog), or CS + iloprost as shown in Fig. 4. For the in vivo studies, we diverted to misoprostol as PGE2 analog, as this is a well-tolerated, safe analog of PGE2 that is also used clinically. To assess the impact of in vivo CS exposure to the apical epithelial side only and to investigate the immediate impact of CS on the alveolar epithelial progenitors, we exposed mice to air or CS for 1 week, subsequently isolated CD31−/CD45−/Epcam+ cells, and cocultured these with CCL-206 fibroblasts in vitro for 14 days (Fig. 4A). The number of alveolar organoids was significantly decreased after in vivo CS exposure, indicating that a relatively short exposure to CS in vivo is sufficient to capture early changes in progenitor cell function (Fig. 4C). CS exposure did not change the yield of CD31−/CD45−/Epcam+ cells, whereas exposing mice to misoprostol or iloprost increased the yield of Epcam+ cells (fig. S6A). The organoid assay revealed that in vivo (intraperitoneal) treatment with either misoprostol or iloprost significantly increased the number of alveolar-type and SPC+ organoids (Fig. 4, E and F) ex vivo. Next, to investigate whether in vitro drug treatment would have similar effects on damage caused by in vivo CS exposure, we isolated Epcam+ cells from either air- or CS-exposed mice and subjected these to in vitro misoprostol or iloprost treatment in the organoid assay for 14 days (Fig. 4G). In vitro misoprostol increased the number of alveolar-type organoids in cultures derived from CS-exposed mice (Fig. 4H). Only in vitro misoprostol increased the size of alveolar organoids derived from CS-exposed animals (fig. S6C). To validate these findings in a chronic CS model, we isolated CD31−/CD45−/Epcam+ cells from mice exposed to CS for 4 months and subjected these cells in vitro to misoprostol or iloprost treatment in the organoid assay for 14 days. In vitro misoprostol and iloprost increased the number of alveolar-type organoids in cultures derived from chronically CS-exposed mice to the same extent as what we observed for the 1-week exposure model (Fig. 4K). Misoprostol also increased the number of SPC+-differentiated organoids (Fig. 4L). Together, our data show that PGE2 and PG12 analogs protect alveolar epithelial progenitor function from the effects of CS exposure. In addition, EP4 rather than EP2 seems to mediate the protective effects of PGE2.

**Distinct genetic signatures in regulation of defective alveolar epithelial repair**

To unravel the transcriptional changes leading to impaired lung organoid formation after exposure to CS and the mechanisms underlying the beneficial effects of PGE2 and PG12 treatment, we performed RNA-seq (Fig. 5A) on Epcam+ cells isolated from mice exposed to air (control), CS, CS + misoprostol (intraperitoneal), or CS + iloprost (intraperitoneal) directly after the isolation procedure (i.e., before inclusion in the organoid assay). Principal component analysis (PCA) revealed that the CS-exposed group is transcriptionally distinct from the control group (Fig. 5B) and that the CS + misoprostol and CS + iloprost groups are transcriptionally different from the CS-exposed group. The top differentially expressed genes from these three comparisons, including both up- and down-regulated genes, are shown in the volcano plot (Fig. 5C) and summarized in the Supplementary Materials. Reactome pathway analysis was used to identify molecular pathways overrepresented in CS/misoprostol/iloprost-modulated genes in alveolar epithelial cells. Within the top 20 enriched pathways (Fig. 5D and the Supplementary Materials), genes associated with cell cycle, mitotic prometaphase, DNA replication/synthesis, and RHO guanosine triphosphatases (GTPases) activating formins signaling pathways were up-regulated by CS exposure compared to air (control) exposure; however, these were down-regulated by treatment with misoprostol or iloprost. Notably, genes associated with the circadian clock signaling pathway were down-regulated by CS exposure but restored by treatment with misoprostol or iloprost. Moreover, signaling by FGFR1, FGFR3, and FGFR4 were down-regulated in response to CS exposure, whereas the same signaling pathways were up-regulated by misoprostol but not iloprost treatment. These findings suggest that the repair mechanisms of misoprostol and iloprost in response to CS include cell cycle and circadian clock signaling and that the distorted FGFR signaling resulting from CS was corrected only by misoprostol. In addition, the nuclear receptor transcription pathway, growth hormone receptor signaling, mitogen-activated protein kinase (MAPK), WNT, and cell-cell communication signaling pathways appear to be down-regulated in response to CS, but not in either the misoprostol or iloprost treatment group. Overall, the RNA-seq analysis demonstrates both common and distinct transcriptomic mechanisms of misoprostol and iloprost treatment in response to CS exposure in alveolar epithelial progenitors.

**Circadian clock signaling and alveolar epithelial repair**

Having demonstrated that the circadian clock signaling pathway was down-regulated by CS exposure and restored by in vivo treatment of misoprostol or iloprost, we next set out to explore this finding in more detail. We assessed the mRNA expression of core circadian clock genes in the lung tissue from patients with COPD (GSE76925) and found that the expression of CRY1, CRY2, RORA, and PER2 were all significantly decreased in COPD (Fig. 6A). We next assessed these same transcriptional nine core circadian clock genes in the mouse lung epithelial cells we obtained after in vivo CS exposure and misoprostol/iloprost treatment (described in Fig. 5A). The gene expression of these clock genes was mostly down-regulated in CS-exposed alveolar epithelial progenitors (Fig. 6B). Misoprostol and iloprost increased the expression of Per2, Per3, and Nr1d2 in particular (Fig. 6B). scRNA-seq of mouse lung tissue showed that these nine core circadian clock genes were mainly expressed in alveolar epithelial cells and fibroblasts (Fig. 6C), whereas CRY1, CRY2, and Nr1d1 were highly expressed in alveolar epithelial cells (Fig. 6C), whereas Clock, Rora, and Nr1d1 were highly expressed in the fibroblasts (Fig. 6D). Among epithelial cell types, the core circadian clock gene Rora was mainly expressed in alveolar epithelial type II cells; among...
mesenchymal cell types, it was mainly expressed in leucine-rich repeat-containing G protein-coupled receptor 5+/6+(Lgr5+/Lgr6+) fibroblasts (Fig. 6, C and D, and fig. S7).

The nuclear heme receptor Rev-erbα, encoded by NR1D1, plays an essential role in clock-dependent lung physiology and anti-inflammatory response (19–21). In line with these findings, the immunofluorescence staining of mouse lung tissue showed that NR1D1 (nuclear receptor subfamily 1, group D, member 1) and PER3 (period circadian clock 3) were expressed at the protein level in alveolar epithelial cells and PER3 was particularly enriched in alveolar epithelial type II cells (Fig. 6E). Next, to functionally evaluate the role of Rev-erbα in defective lung repair, we used an agonist and antagonist of Rev-erbα (Fig. 6, F and G). The Rev-erbα agonist GSK4112 (10 μM) increased the number of alveolar-type organoids, both compared to vehicle and in the presence of 5% CSE (Fig. 6H). Conversely, the Rev-erbα antagonist SR8278 (10 μM) significantly prevented organoid formation (Fig. 6H), both in the absence and in the presence of 5% CSE.

**DISCUSSION**

COPD results from repeated microinjuries to the epithelium often caused by tobacco smoking. In susceptible individuals, this results in tissue remodeling in the conducting airways but destruction of the respiratory bronchioles and alveoli (22). Such a disparity was also found in our organoid assay, which revealed higher numbers of...
airway organoids but lower numbers of alveolar organoids in response to in vivo CS exposure. No clinically approved pharmacological treatment prevents or reverses the tissue destruction in the distal lung. The results of our study are in line with this contention and demonstrate that the PDE4 inhibitor rolipram and the corticosteroid budesonide appeared to restrict progenitor cell growth, which is a concern, given the wide use of corticosteroids in the management of COPD. These results suggest that novel targets may be a better alternative. PGE2 is the most widely produced PG and may be a better alternative. PGE2 has been reported as an unstable molecule with an extremely short half-life; therefore, targeting its receptors with specific more stable analogs may be a better alternative. PGE2 is the most widely produced PG in the human body, and it signals via four specific G protein–coupled receptors (EP1 to EP4). We show EP receptors to have similar expression as in non-COPD controls, whereas IP receptors are expressed at higher levels in patients with COPD, indicating that the expression of both receptors is maintained in disease.

We show that PGE2 agonists are beneficial in reducing CS-induced damage to alveolar epithelial progenitors. However, PGE2 has been reported as an unstable molecule with an extremely short half-life; therefore, targeting its receptors with specific more stable analogs may be a better alternative. PGE2 is the most widely produced PG in the human body, and it signals via four specific G protein–coupled receptors (EP1 to EP4). The interactions between PGE2 and EP receptors depend on tissue and cell type, specific receptor expression, and differences in binding affinities, leading to unique patterns of EP receptor activation. PGE2 can stimulate cAMP production through EP2 and EP4 receptors, whereas EP3 activation results in decreased cAMP synthesis and EP1 stimulation is coupled
expression of PGE2 in the human lung (COPD and in smokers. Smoking and aging are associated with 37), Expression of the EP4 receptor is maintained in bronchoprotection (in humans; EP2 in mice) (36) and inhibition of inflammation (37). Expression of the EP4 receptor is maintained in COPD and in smokers. Smoking and aging are associated with increased expression of PGE2 in the human lung (38, 39). Whereas this may serve as an endogenous protective mechanism, PGE2 has multiple effects, and not all of these are protective to the pathophysiology of COPD. We propose that selective EP4 agonism could unify several functional features that support the treatment of COPD, making this an intriguing pharmacological target.

Iloprost, a stable PG12 analog (30, 40–44), has been shown to have anti-inflammatory effects and protects against bleomycin-induced pulmonary fibrosis in mice (41) and is also clinically used for the treatment of pulmonary hypertension (40). Although a recent study (43) showed that iloprost improved clinical outcomes in patients with COPD with poor lung oxygenation, its impact on alveolar repair is unknown. Here, we show that iloprost prevents the repressed organoid formation resulting from CS(E) exposure. Whereas IP and EP4 receptors are both linked to cAMP generation, rolipram and olodaterol had no effect on organoid growth and only very limited effect when applied in combination. This apparent discrepancy might be explained by cAMP compartmentalization. This phenomenon explains why and how distinct Gq protein–coupled receptors or drugs activating the cAMP pathway can have distinct effects on cAMP generation and function (45). An alternative explanation is that EP4 receptor expression is higher than that of the β2-adrenergic receptor. As corticosteroids have been shown to inhibit the release of arachidonic acid metabolites including PG12 (46) and PGE2 (17), we speculate that the negative effect of budenoside on the progenitor cell growth may be due to the restriction of PG synthesis.

Analogs of PGE2 and PG12 have previously been demonstrated to attenuate other features of COPD in mice. For example, iloprost attenuated inflammation, airway hyperresponsiveness, and airway remodeling in a mouse model of lipopolysaccharide and elastase exposure (45). Systemically administered EP2 agonists have beneficial effects on angiogenesis in a mouse model of emphysema (45). Moreover, PGE2 represses fibroblast activation, fibroblast to myofibroblast differentiation, and migratory capacity (47). PGE2 has been reported (48) as a key regulator released from alveolar epithelial cells regulating the barrier function of the lung microvasculature. However, we did not see supportive effects of misoprostol or iloprost using a scratch wound assay on human pulmonary endothelial cells exposed to CS (fig. S8), indicating that the beneficial effects of PGE2 and PG12 on repair may be specific for the alveolar epithelial cell. In addition, studies have shown PGE2 to be anti-inflammatory by attenuating macrophages activation and proliferation (39, 49). While beneficial, the anti-inflammatory activity of PGE2 and PG12 analogs could also predispose to pulmonary infections, which is a risk that needs to be considered moving forward. Here, we identified the potential therapeutic effect of PGE2 and PG12 analogs on defective alveolar progenitors in response to CS that appears to be primarily related to the disturbance of circadian clock signaling rather than its anti-inflammatory response. Given the diverse and occasionally opposite roles of PGE2 and PG12 in the pathophysiology of COPD, the main challenge will be to balance broad spectrum with specificity, for example, using subtype-selective drugs or drugs targeted to specific lung cell types.

By generating transcriptomic signatures of epithelial progenitors derived from mice exposed in vivo to air, CS, CS + misoprostol, or CS + iloprost, we uncovered dynamic molecular signaling pathways in response to CS exposure. We identified circadian clock signaling as being significantly repressed in the alveolar epithelial progenitors derived from mice exposed to CS, which could be improved by either misoprostol or iloprost treatment. Circadian rhythms (50–53) are normally generated and regulated by clock genes, including BMAL1 (ARNTL1) and CLOCK encoding activators, period (PER1 to PER3) and cryptochrome genes (CRY1 and CRY2) that encode repressors, and the nuclear receptors Rev-erbα (NR1D1 and NR1D2) and RORA, which constitute secondary regulatory loops. These core clock genes not only activate or repress a cell-autonomous clock but also regulate the clock-controlled genes (54), thus interacting with other molecular signaling pathways. Previously, it has been demonstrated that clock signaling is downregulated in CS–exposed mice, linked to an impairment of antioxidant defense mechanisms (55), and Rev-erbα has been shown as an key regulator of inflammatory response in lung injury models (19–21, 56). Here, we show that the Rev-erbα agonist prevents the impaired organoid formation resulted from CSE exposure, suggesting that PGE2/PG12/Rev-erbα signaling pathway plays an important role in defective lung repair.

Furthermore, we found that CS exposure up-regulated pathways associated with cell cycle activity in alveolar epithelial progenitors, which could be counteracted by in vivo misoprostol or iloprost treatment. The cell cycle (57–61) is driven by a set of tightly regulated molecular events controlling DNA replication and mitosis with four phases, and each individual cell may require different triggers to decide whether to enter proliferation or apoptosis. To further assess alveolar epithelial progenitors under which cell cycle/apoptotic status in response to CS exposure and additional PGE2/PG12 treatments may be the next step to investigate in the future. A link between circadian clock and cell cycle signaling pathways has been proposed (54, 60, 62). The molecular control of the biological clock is dependent on cAMP signaling, and cAMP activators are known to entrain the biological clock (63), explaining the link between PGE2 and PG12 activations and restoration of the defective clock signaling in combination with CS exposure. Hence, it is of great interest to determine in more molecular detail how these two oscillatory systems communicate in regulating PGE2/PG12-mediated lung repair in future studies.

In conclusion, in this study, we demonstrate the protective effects of several drug candidates, including PGE2 and PG12 analogs, against in vivo and in vitro CSE-induced damage of alveolar epithelial progenitors. Furthermore, using transcriptome analysis, we show that CS induces a wide range of transcriptional changes, including alterations of circadian clock and cell cycle signaling pathways, which can be counteracted by either misoprostol (PGE2) or iloprost (PG12) treatment. While the focus of our studies was on COPD, similar beneficial effects may be operative in diseases affected...
by similar defects in alveolar progenitors such as acute respiratory distress syndrome and pulmonary fibrosis. Overall, these data provide promising therapeutic strategies to specifically address defective lung repair in respiratory diseases, in particular, targeting EP4 and IP receptors.

**MATERIALS AND METHODS**

**Animals**

Mouse experiments for organoid study were performed at the Central Animal Facility of the University Medical Center Groningen (UMCG) in accordance with the national guidelines and upon approval of the experimental procedures by CDP and the Institutional Animal Care and Use Committee of the University of Groningen (license AVD105002015303). C57BL/6J (555) and BALB/cByJ (Jax strain) mice (both genders, 8 to 12 weeks of age) were maintained under a 12-hour light/dark cycles and were allowed food and water ad libitum. Animals for circadian clock studies were exposed to CS and/or administrated with compounds at the same time of the day for all mice in all groups. Animals were euthanized at the same time of the day. Animals for the chronic CS model were adult (female, 8 to 10 weeks of age at the start of the study) C57BL/6N mice, which were obtained from the Charles River Laboratories (Sulzfeld, Germany) and used for both the scRNA-seq analysis and organoid assay. These experiments were performed at the Helmholtz Zentrum München and approved by the ethics committee for animal welfare of the local government for the administrative region of Upper Bavaria (Regierungspräsidium Oberbayern) and were conducted under strict governmental and international guidelines in accordance with European Union Directive 2010/63/EU.

**Human material**

The human lung tissue was obtained from lung transplant donors according to the Eurotransplant guidelines including the absence of primary lung diseases such as asthma and COPD and no more than 20 pack years of smoking history. Human lung tissue specimens were obtained with full informed consent from patients undergoing lung volume reduction surgery or lung transplantation at UMCG. The human lung tissue was obtained from lung transplant donors according to the Eurotransplant guidelines including the absence of primary lung diseases such as asthma and COPD and no more than 20 pack years of smoking history. Human lung tissue specimens were obtained with full informed consent from patients undergoing lung volume reduction surgery or lung transplantation at UMCG. All tissue samples were anonymized before use. Gene expression in human lung published datasets was obtained by downloading a series matrix files from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database for GSE76925 (65) and gene expression normalized to healthy smokers.

**In vivo CS exposure**

Mice (n = 4 to 11 per group, 10 to 12 weeks old) were exposed (whole body) to 3R4F research cigarettes (Tobacco Research Institute, University of Kentucky, Lexington, KY) for four consecutive days (two sessions per day, 8 hours between each exposure) to establish an acute smoke-induced inflammation model, as described previously (9). In the CS group, mice were exposed to one cigarette in the morning and three in the afternoon on day 1. From days 2 to 4, mice were exposed to five cigarettes each session. All cigarettes were smoked without a filter in 5 min at a rate of 5 liter/hour in a ratio with 60 liter/hour air using a peristaltic pump (45 rpm; Watson Marlow 323 E/D, Rotterdam, the Netherlands). In the control group, mice were exposed to fresh air using similar exposure chambers as the CS group.

In some studies, budesonide was nebulized (0.1 mM; 15 min per mouse per exposure) to wild-type mice (n = 6) before each CS exposure. In separate studies, intraperitoneal injections of 50 μg of misoprostol or 50 μg of iloprost were given to wild-type mice (n = 6 to 8) 30 min before each CS exposure. On day 5, mice were euthanized, and the lungs were immediately used for establishing organoid cultures or stored at −80°C for further experimental uses.

For the scRNA-seq analysis and the organoid assay setup in the chronic model, CS was generated from 3R4F research cigarettes, with the filters removed to expose to the murine lungs. Mice were whole body exposed to active 100% mainstream CS of 500 mg/m³ total particulate matter for 50 min twice per day for 4 m in a manner mimicking natural human smoking habits as previously described (65).

**Fibroblast culture**

Mouse fibroblasts, CCL-206 [Mlg (CCL-206); American Type Culture Collection (ATCC), Wesel, Germany] were cultured in Dulbecco's modified Eagle’s medium (DMEM)/F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin/streptomycin (100 U/ml), 2 mM l-glutamine, and 1% amphotericin B in a humidified atmosphere under 5% CO₂/95% air at 37°C, as previously described (6, 10, 66). For organoid experiments, fibroblasts were proliferation-inactivated by incubation in mitomycin C (10 μg/ml; M4287, Sigma-Aldrich) for 2 hours, followed by three washes with phosphate-buffered saline (PBS), after which the cells were trypsinized before introduction into the organoid cocultures. Human lung fibroblasts MRC5 (CCL-171, ATCC, Wesel, Germany) were cultured in Ham’s F12 medium supplemented with the same additives as the murine fibroblasts’ medium.

**Cigarette smoke extract**

The smoke of two 3R4F research cigarettes was pumped into 25 ml of warm fibroblasts culture medium to produce 100% CSE (12). Cigarette smoke extracts were without a filter, and smoke was passed through the medium using a peristaltic pump (45 rpm; Watson Marlow 323 E/D, Rotterdam, the Netherlands). CSE was freshly prepared before each set of experiments.

**Murine primary alveolar epithelial isolation**

The primary alveolar epithelial cells, brief in Epcam⁺ cells (CD31⁻/CD45⁻/CD326⁺) were isolated on the basis of the protocols published previously from our group (67). The isolation of Epcam⁺ cells generated from the chronic CS mice was slightly different. Murine lungs harvested from mice exposed with CS (4 months) were stored in MACS tissue storage solution (130-100-008) at 4°C overnight (due to shipment). Lungs were chopped into small pieces and incubated in the enzyme mix containing dispase (#354235, Corning) and deoxyribonuclease I (A3778, Analytics-Shop) for 1 hour at 37°C. The rest procedure is the same as the ordinary epithelial isolation.

**Organoid culture**

The adult alveolar epithelial progenitor cell–derived organoid assay provides a platform to study the response of alveolar epithelial cells to various conditions rapidly and easily where complex in vivo analysis is less feasible (68) and typical two-dimensional cell culture cannot recapitulate the cell–cell interactions. Moreover, organoids represent a powerful tool to model various pathological states of environmental or genetic origin that can be easily manipulated.
in vitro for validation of therapeutic approaches (69). The organoid culture system is based on previously published protocols from our group (6, 10, 66). Briefly, epithelial cells (CD31+/CD45-/CD326+) were freshly isolated from murine or human lung tissue and co-cultured with murine CCL-206 or human MRC5 fibroblasts, respectively, in Matrigel (Corning Life Sciences B.V., Amsterdam, The Netherlands). EpCAM⁺ (CD31+/CD45+/CD326+) cells were isolated from mouse lung tissue (without the trachea) using the QuadroMACS Separator and antibody-bound magnetic beads (Miltenyi Biotec, Leiden, The Netherlands). EpCAM⁺ cells and fibroblasts were mixed 1:1 (20,000 cells each) and suspended in 100 µl of Matrigel prediluted 1:1 (v/v) with DMEM supplemented with 10% FBS. This mixture of cells was added to a 24-well Falcon cell culture insert (Corning, USA) within a 24-well plate containing 400 µl of organoid media [DMEM/F-12 supplemented with 5% FBS, 1% penicillin/streptomycin, 1% glutamine, 1% amphotericin B, 0.025 per mil (%) epidermal growth factor, 1% insulin-transferrin-selenium, and 1.75% bovine pituitary extract] underneath the insert in each well. Adult human donor tissue was isolated from histologically normal regions of lung tissue specimens obtained at UMCG (Groningen, The Netherlands) from n = 7 patients (two non-COPD and five patients with COPD). Human lung tissues were incubated and homogenized overnight in an enzyme mixture at 4°C; the EpCAM⁺ isolation process was similar to that described above for murine lung tissue. Organoids were cultured in a humidified atmosphere under 5% CO₂/95% air at 37°C, and medium in the well was refreshed every 2 to 3 days. To quantify the number of organoids, light microscopy at ×20 magnification was used, and organoids were counted manually. The diameter of the organoid (organoid size) was measured using NIS-Elements software with a light microscope. The number parameter represents the ability of alveolar epithelial progenitors to form organoids, whereas the size parameter may result from swelling or proliferation. Subsequent phenotyping identifies effects on alveolar type II cell differentiation.

For in vitro organoid experiments, organoids were continuously treated with control, 1.25 (1% for human organoids), 2.5, or 5% CSE; and organoid culture medium was refreshed every other day. All information about the pharmacological compounds used in this study is provided in the table S1.

Immunofluorescence staining

The immunofluorescence staining assay for organoids was performed as described previously by our group with minor modifications (6, 10, 66). Organoids were fixed in acetone diluted 1:1 (v/v) with methanol for 15 min at −20°C. After fixation, 1 ml of PBS with 0.02% sodium azide was added to the well underneath the insert. Organoids were kept at 4°C for 1 week after fixation. Bovine serum albumin (BSA) medium was added on top of the insert for blocking at room temperature (RT) for 2 hours. Afterward, primary antibody incubation was performed in PBS buffer with 0.1% BSA and 0.1% Triton X-100 overnight at 4°C. The next day, the organoids were washed three times with PBS for 30 min, and secondary antibody incubation was performed for 2 hours at RT. After washing with PBS for 15 min, the organoids on the insert membrane were transferred to a glass slide with two drops of mounting medium containing 4 the organoids on the insert (DAPI) (104139, Abcam, Cambridge, UK), and a coverslip was applied. The immunofluorescence staining assay for the lung slices was performed as described previously with minor modifications (6).

RNA extraction and RNA-seq analysis

The Epcam⁺ cells isolated from mice exposed to air, CS, CS + misoprostol, or CS + iloprost were used to extract total RNA for RNA-seq using NucleoSpin RNA kit (740955, Macherey-Nagel, Germany) according to the manufacturer’s instructions. RNA concentrations and qualities were analyzed using NanoDrop spectrophotometer. An Illumina NovaSeq 6000 sequencer was used for the RNA-seq data analysis by GenomeScan (www.genomescan.nl). The procedure included data quality control, adapter trimming, alignment of short reads, and feature counting. Library preparation was checked by calculating the ribosomal (and globin) content. Checks for possible sample and barcode contamination were performed, and a set of standard quality metrics for the raw dataset was determined using quality control tools (FastQC v0.34 and FastQA). Before alignment, the reads were trimmed for adapter sequences using Trimmomatic v0.30. To align the reads of each sample, the ensemble mouse reference GRCm38 (patch 6) was used. Analyses following the RNA-seq studies were performed using the Biojupies platform (https://amp.pharm.mssm.edu/biojupies/) (70) and using the DeSeq2 package in R. Gene expression in murine lung published datasets was obtained by downloading a series of matrix files from the NCBI GEO database (GSE151674).

Immunohistochemistry

Immunohistochemistry was performed on the murine lung tissue harvested from mice exposed by air/CS/CS + misoprostol (intraperitoneal)/CS + iloprost (intraperitoneal) based on the optimized protocol described previously (71). Briefly, paraffin-embedded frozen murine lung tissue was cut with a Microm HM 340E microtome. Five-micrometer transverse cross sections were used for analysis. Tissue sections were first dried 30 min with hair blower and then were rehydrated in PBS. Tissue sections were stained with 3,3’-diaminobenzidine (DAB) (Sigma-Aldrich) NaN₃ and H₂O₂ for 7 min. After rising within PBS, sections were counterstained with hematoxylin and imbedded in Kaiser gelatin. Sections were stained with Mayer’s hematoxylin for 10 min, rinsed in running tap water for 10 min, and then were stained with eosin for 3 min. After a short rinsing step (UP water), the sections were quickly dehydrated in 96% ethanol and 100% ethanol and xylene. The section was mounted with mounting medium.
Statistics analysis
All data are presented as means ± SEM unless indicated otherwise. Unless stated otherwise, all data were assessed for statistical significance using two-tailed Student’s t test or one-way analysis of variance (ANOVA). The P value indicating statistically significant differences between the mean/median values are defined as follows: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Statistical analyses were performed with GraphPad Prism 8 software.

SUPPLEMENTARY MATERIALS

Supplementary material for this article is available at https://science.org/doi/10.1126/sciadv.abj9949

REFERENCES AND NOTES

1. N. Kokturk, F. Yildirim, P. Y. Gulhan, Y. M. Oh, Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic? Am. J. Stem Cells. 7, 56–71 (2018).
2. M. C. Basil, J. Katzen, A. E. Engler, M. Guo, M. J. Herriges, J. J. Kathiriya, R. Windmueller, A. B. Ysai, W. J. Zacharias, H. A. Chapman, D. N. Kotron, J. R. Rock, H. W. Snoch, G. Junak-Novakovic, J. A. Whitsett, E. E. Morrisey, The cellular and physiological basis for lung repair and regeneration: Past, present, and future. Cell Stem Cell 26, 482–502 (2020).
3. T. Volckaert, T. Yuan, C. M. Chao, H. Bell, A. Sitaua, L. Szaimitenmes, E. El Agha, D. Chanda, S. Majka, S. Bellusci, V. J. Thannickal, R. Fassler, S. P. De Langhe, Fgf10-hippo epithelial-mesenchymal crosstalk maintains and recruits lung basal stem cells. Dev. Cell 43, 48–59.e5 (2017).
4. Y. Hu, J. P. Ng-Blichfeldt, C. Ota, C. Cimini, W. Ren, P. S. Hiemstra, J. Stolk, R. Gosens, M. Könighoff, Wntβ-catenin signaling is critical for regenerative potential of distal lung epithelial progenitor cells in homeostasis and emphysema. Stem Cells 38, 1467–1478 (2020).
5. T. M. Conlon, G. John-Schuster, D. Heide, D. Pfister, M. Lehmann, Y. Hu, Z. Ertüz, et al., Sci. Adv. 8, eabj9949 (2022).

© 2023 American Association for the Advancement of Science.
38. M. Profita, A. Sala, A. Bonanno, L. Riccobono, M. Ferraro, S. La Grutta, G. D. Albano, A. M. Montalban, M. Gomarkaj, Chronic obstructive pulmonary disease and neutrophil infiltration: Role of cigarette smoke and cyclooxygenase products. Am. J. Physiol. Lung Cell. Mol. Physiol. 298, L1261–L1269 (2010).

39. L. R. Penke, J. M. Speth, C. Draijer, Z. Zaslona, J. Chen, P. Mancuso, C. M. Freeman, J. L. Curtis, D. R. Goldstein, M. Peters-Golden, PGE2 accounts for bidirectional changes in alveolar macrophage self-renewal with aging and smoking. Life Sci. Alliance. 3, e202008800 (2020).

40. L. Wang, Y. Z. Jin, Q. H. Zhao, R. Jiang, W. H. Wu, S. G. Gong, J. He, J. M. Liu, Z. C. Jing, Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension. Int. J. COPD. 12, 3353–3360 (2017).

41. Y. Zhu, Y. Liu, W. Zhou, R. Xiang, L. Jiang, H. Huang, Y. Xiao, Z. Guo, J. Gao, A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir. Res. 11, 34 (2010).

42. B. Gohrbandt, S. P. Sommer, S. Fischer, J. M. Hofhüfeld, G. Warnecke, A. Haverich, M. Strueber, Iloprost to improve surfactant function in porcine pulmonary grafts stored for twenty-four hours in low-potassium dextrose solution. J. Thorac. Cardiovasc. Surg. 129, 80–86 (2005).

43. N. Kim, S. H. Lee, Y. Joe, T. Kim, H. Shin, Y. J. Oh, Effects of inhaled iloprost on lung mechanics and myocardial function during one-lung ventilation in chronic obstructive pulmonary disease patients combined with poor lung oxygenation. Anesth. Analg. 130, 1407–1414 (2020).

44. S. H. Lee, J. G. Lee, C. Y. Lee, N. Kim, M. Y. Chang, Y. C. You, H. J. Kim, H. C. Paik, Y. J. Oh, Effects of intraoperative inhaled iloprost on primary graft dysfunction after lung transplantation: A retrospective single center study. Medicine 95, e3975 (2016).

45. M. Schmidt, I. Cattani-Cavallieri, F. N. Juñez, R. S. Ostrom, Phosphodiesterase isoforms and cAMP compartments in the development of new therapies for obstructive pulmonary diseases. Curr. Opin. Pharmacol. 51, 34–42 (2020).

46. Z. J. Wang, D. J. Wilkie, R. Molokoe, Neurophysiologic mechanisms of pain in sickle cell disease. Hemostasis 2010, 403–408 (2010).

47. E. Elwakkeel, B. Brüne, A. Weigert, PGE, in fibrosis and cancer: Insights into fibroblast activation. Prostaglandins Other Lipid Mediat. 143, 106339 (2020).

48. T. Bämtbächer, J. Maric, W. Platzer, V. Konya, A. Theiler, C. Hasenböhl, B. Gottschalk, S. Trautmann, Y. Schreiber, W. F. Graier, G. Marsche, A. Olschewski, D. Thomas, R. Schülzig, A. Heinemann, The role of PGE2 in alveolar epithelial and lung microvascular endothelial endothostalk. Sci. Rep. 7, 7923 (2017).

49. L. S. Saleh, C. Vanderheyden, A. Fredericsson, S. J. Bryant, Prostaglandin E2 and its receptor EP2 modulate macrophage activation and fusion in vitro. ACS Biomater Sci. Eng. 6, 2668–2681 (2020).

50. A. Gallardo, A. Molina, H. G. Asenjo, J. Martorell-Marugán, R. Montes, V. Ramos-Mejía, A. Gallardo, A. Molina, H. G. Asenjo, J. Martorell-Marugán, R. Montes, V. Ramos-Mejía, 8 of 14 of 14

51. S. Almeida, M. Chaves, F. Delaunay, Control of synchronization ratios in clock/cell cycle coupling by growth factors and glucocorticoids. R. Soc. Open Sci. 7, 192054 (2020).

52. U. Abraham, A. E. Granada, P. O. Westermark, M. Heine, A. Kramer, H. Hezel, Coupling governs entrainment range of circadian clocks. Mol. Syst. Biol. 6, 438 (2010).

53. X. Zou, D. W. Kim, T. Gotoh, J. K. Kim, C. V. Finkielstein, A systems biology approach to uncover molecular cogs that control of copd and role of pharmacotherapy: A review. Int. J. COPD. 1269–1285 (2020).

54. J. Gaucher, E. Montellier, P. Sassone-Corsi, Molecular Cogs: Interplay between circadian mechanisms and cellular responses. Cell. Mol. Physiol. 47, L14–L28 (2019).

55. X. Wu, V. Verschut, M. E. Woest, P. J. Ng-Blichfeldt, A. Matias, G. Villetti, A. Accetta, F. Facchinetti, R. Gosens, L. E. M. Kistemaker, Rho-kinase 1/2 inhibition prevents transforming growth factor-j-induced effects on pulmonary remodelling and repair. Front. Pharmacol. 11, 609509 (2021).

56. M. C. Bas, E. E. Morrissey, Lung regeneration: A tale of mice and men. Semin. Cell. Dev. Biol. 100, 88–100 (2020).

57. M. Paschini, C. F. Kim, An airway organoid is forever. EMBO J. 38, e101526 (2019).

58. D. Torre, A. Lachmann, A. Ma’ayan, Biojupiies: Automated generation of interactive notebooks for RNA-Seq data analysis in the cloud. Cell Syst. 7, 556–561.e3 (2018).

59. T. Roopmans, L. Hesse, M. C. Nawijn, K. Kumawat, H. M. Menzen, I. Sophie, R. Smits, E. R. M. Bakker, M. van den Berge, G. H. Koppelman, V. Guryev, R. Gosens, Smooth-muscle-derived WNT5A augments allergen-induced airway remodelling and Th2 type inflammation. Sci. Rep. 10, 6754 (2020).

Acknowledgments: Funding: We acknowledge the support from the Lung Foundation Netherlands (Longfonds, grant S.11.17.166) to R.G. and M.K., China Scholarship Council (CSC201707720065) to X.W., and Molecular Life and Health Scholarship from the University of Groningen to L.v.d.K. We acknowledge the support from the Lung Foundation Netherlands (Longfonds, grant 5.1.1.17.166) to R.G. and M.K., China Scholarship Council (CSC201707720065) to X.W., and Molecular Life and Health Scholarship from the University of Groningen to L.v.d.K. Author contributions: X.W. and R.G. conceptualized the project and analyzed and interpreted the data. R.G., L.E.M.K., and M.S. supervised the project. J.W., A.M.K., L.E.M.K., A.O.Y., and R.G. designed the experiments. X.W., I.S.T.B., V.V., L.v.d.K., L.A.V., and A.D. performed the experiments. L.M.C., T.M.C., and H.B.S. prepared the figures. T.M.C., M.A., H.B.S., and A.Ö.Y. contributed to the data. R.G., L.E.M.K., and M.S. supervised the project. X.W., A.M., M.K., L.E.M.K., A.Ö.Y., and R.G. drafted the manuscript. All authors reviewed and commented on the manuscript and agreed to the final version. Competing interests: V.V. and L.E.M.K. are employees of Aquilo BV. R.G. and M.K. are members of the BREATH consortium funded by the Lung Foundation Netherlands (Longfonds). The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Submitted 18 June 2021

Accepted 15 December 2021

Published 23 March 2022

10.1126/sciadv.abj9949

14 of 14